Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-08-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：2025年半年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage, management, and actual use of funds raised in the first half of 2025 by Shanghai Medicilon Inc. It includes specifics on the amount raised, usage, management policies, investment projects, and compliance with regulatory requirements. The document references regulatory rules related to fundraising and includes financial figures and tables about the use of raised funds. It is not an announcement of a report but the report itself, containing substantive financial data and analysis about fundraising activities for a half-year period. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (9447 characters) and content confirm it is a full report, not a brief announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-08-28 Chinese
美迪西：信息披露事务管理制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is a detailed internal management system for information disclosure of Shanghai Medicilon Inc., covering principles, responsibilities, procedures, and regulatory compliance related to information disclosure. It extensively references regulatory requirements, types of reports (annual, interim, quarterly, temporary), and disclosure obligations but does not itself contain financial statements, audit opinions, or actual financial results. It is a governance and procedural document outlining how the company manages information disclosure to comply with laws and stock exchange rules. It is not an annual report, earnings release, audit report, or any specific financial report. It is not a short announcement or certification but a comprehensive internal policy document. Therefore, it best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices related to disclosure.
2025-08-28 Chinese
美迪西：内部审计管理制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled '内部审计管理制度' which translates to 'Internal Audit Management System' and details the internal audit policies, responsibilities, organizational structure, and procedures of the company Shanghai Medicilon Inc. It is a comprehensive internal governance document focused on internal audit management rather than a financial report or announcement. It does not contain financial statements, earnings data, or shareholder voting results. It is not a report publication announcement or a certification. The content aligns with internal governance and audit management practices, which fits best under Governance Information (CGR).
2025-08-28 Chinese
美迪西：2025年限制性股票激励计划（草案）摘要公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a 2025 restricted stock incentive plan (股权激励计划) by Shanghai Medicilon Inc. It includes specifics about the stock incentive plan's purpose, stock source, number of shares, eligibility, grant price, vesting conditions, accounting treatment, and procedures. The content is regulatory and compliance-focused, detailing the plan's structure and legal basis, typical of a capital or financing update related to equity incentives. It is not a full financial report, earnings release, or management discussion, nor is it a simple announcement or proxy statement. The document is lengthy (15,000 characters) and contains substantive details about the stock incentive plan, which is a capital structure change and financing-related update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-08-28 Chinese
美迪西：关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 second extraordinary general meeting of shareholders for Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods, agenda items, registration procedures, and proxy forms. The content focuses on the announcement and logistics of the shareholder meeting rather than the results of voting or the meeting minutes. It does not contain financial statements or management discussion but is a formal notification to shareholders about the meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-08-28 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司增加2025年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (广发证券股份有限公司) regarding the verification and review of increased expected daily related-party transactions for the year 2025 by Shanghai Medicilon Inc. (上海美迪西生物医药股份有限公司). It includes detailed transaction amounts, related parties, board and supervisory committee approvals, independent director opinions, and compliance with relevant laws and company articles. The document is not an announcement of a report publication but contains substantive content about the related-party transactions and their review. It is not a financial report like an annual or interim report, nor is it a regulatory filing or a voting result announcement. It is a specialized audit or verification report related to internal controls and compliance on related-party transactions, which fits the category of Audit Report / Information (AR). The document length is 4068 characters, which is substantive but not overly long, consistent with an audit or verification report rather than a full annual report or earnings release. FY 2025
2025-08-28 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.